Ernexa Therapeutics (Nasdaq: ERNA) has moved its lead cell therapy, ERNA-101, from the lab into Good Manufacturing Practice production. The company announced the step on May 27, 2026.
In plain terms, GMP is the regulated way of making a drug that will go into people. Ernexa said it finished process development for ERNA-101, then shifted to GMP manufacturing to prepare for clinical development. Technology transfer work is running at the same time. The company calls that another major operational milestone behind its timetable.
The target date is the third quarter of 2026, when Ernexa plans to file an Investigational New Drug application. Clearance would open the way for a first-in-human study and, in the company’s words, a transformation into a clinical-stage biotechnology firm.
“Completing process development and advancing into GMP manufacturing are critical steps toward IND clearance and the launch of our first-in-human clinical study for ERNA-101,” said CEO Sanjeev Luther. He said the team was “executing against our development strategy with urgency and discipline.” On technology transfer, Luther added that Ernexa believes it is “entering a transformational phase.”
He also said the therapy could “bring new hope to patients and families in need of better therapeutic options.”
What ERNA-101 is
Ernexa builds its cell therapies from induced pluripotent stem cells, which it turns into induced mesenchymal stem cells, or iMSCs. The cells are allogeneic, meaning they are not drawn from each patient. Think of it as an off-the-shelf product: no patient-specific cell harvesting is needed.
ERNA-101 is the lead product. The company designed it to activate and regulate the immune system’s response so that the body recognizes and attacks cancer cells. Ernexa’s first target is ovarian cancer. A second candidate, ERNA-201, is meant to address inflammation and treat autoimmune disease.
Ernexa is developing its therapies for advanced cancer and autoimmune disease. The company listed the milestones as an IND submission aimed at Q3 2026, technology transfer in progress, completed process development and a GMP transition underway.
